Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Management of treatment-related adverse events in patients with multiple myeloma.

Mateos MV.

Cancer Treat Rev. 2010 May;36 Suppl 2:S24-32. doi: 10.1016/S0305-7372(10)70009-8. Review.

PMID:
20472185
2.

Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

Palumbo A, Mateos MV, Bringhen S, San Miguel JF.

Blood Rev. 2011 Jul;25(4):181-91. doi: 10.1016/j.blre.2011.03.005. Epub 2011 Apr 16. Review.

PMID:
21497966
3.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

4.

(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.

Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.

Ann Hematol. 2012 Nov;91(11):1779-84. doi: 10.1007/s00277-012-1520-4. Epub 2012 Jul 7.

PMID:
22773209
5.

Management of the adverse effects of lenalidomide in multiple myeloma.

González Rodríguez AP.

Adv Ther. 2011 Mar;28 Suppl 1:1-10. doi: 10.1007/s12325-010-0104-8. Epub 2011 Mar 9. Review.

PMID:
21431626
6.

How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.

Mateos MV.

Leuk Res. 2012 Nov;36 Suppl 1:S35-43. doi: 10.1016/S0145-2126(12)70007-3. Review.

PMID:
23176723
7.

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.

Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K.

J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12. Erratum in: J Natl Compr Canc Netw. 2010 Mar;8(3):xlv. Dosage error in article text.

PMID:
20141673
8.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83. Review.

PMID:
21322778
9.

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.

von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, Hoffmann F, Naumann R, Bargou R, Cook G, Glasmacher A.

Eur J Haematol. 2008 Oct;81(4):247-52. doi: 10.1111/j.1600-0609.2008.01121.x. Epub 2008 Jul 10. Review.

10.

Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.

Pérez Persona E, Mesa MG, García Sánchez PJ, González Rodríguez AP.

Adv Ther. 2011 Mar;28 Suppl 1:11-6. doi: 10.1007/s12325-010-0102-x. Epub 2011 Mar 9.

PMID:
21431627
11.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
12.

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.

Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P.

Lancet Oncol. 2010 Nov;11(11):1086-95. doi: 10.1016/S1470-2045(10)70068-1. Review.

PMID:
20932799
13.

Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.

Koeppen S.

Oncol Res Treat. 2014;37(9):506-13. doi: 10.1159/000365534. Epub 2014 Aug 14. Review.

PMID:
25231692
14.

Management of older patients with multiple myeloma.

Gay F, Palumbo A.

Blood Rev. 2011 Mar;25(2):65-73. doi: 10.1016/j.blre.2010.10.003. Epub 2011 Feb 4. Review.

PMID:
21295387
15.

[Thrombotic complications following the treatment of multiple myeloma with new agents].

Rupa-Matysek J, Gil L, Komarnicki M.

Pol Merkur Lekarski. 2011 Dec;31(186):372-7. Review. Polish.

PMID:
22239010
16.

Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.

Patrizi A, Venturi M, Dika E, Maibach H, Tacchetti P, Brandi G.

Cutan Ocul Toxicol. 2014 Mar;33(1):1-6. doi: 10.3109/15569527.2013.787086. Epub 2013 May 2.

PMID:
23638756
17.

Multiple myeloma.

Crawford CL.

N Engl J Med. 2005 Feb 24;352(8):840-1; author reply 840-1. No abstract available.

PMID:
15736295
18.

New drugs for myeloma.

Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.

Oncologist. 2007 Jun;12(6):664-89. Review.

19.

Management of relapsed and relapsed refractory myeloma.

Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.

Hematol Oncol Clin North Am. 2007 Dec;21(6):1175-215, x. Review.

PMID:
17996594
20.

Supportive therapies in multiple myeloma.

Gleason C, Nooka A, Lonial S.

J Natl Compr Canc Netw. 2009 Oct;7(9):971-9. Review.

PMID:
19878640

Supplemental Content

Support Center